WestChina Hospital
Welcome,         Profile    Billing    Logout  
 21 Trials 
8 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
yang, li
NCT05463965: A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines

Completed
3
605
RoW
QM1114-DP, OnabotulinumtoxinA, Placebo
Galderma R&D
Moderate to Severe Glabellar Lines
01/23
06/23
NCT06775860: ICP-332 in Subjects with Moderate to Severe Atopic Dermatitis

Recruiting
3
552
RoW
ICP-332 Tablets, ICP-332 Placebo Tablets
Beijing InnoCare Pharma Tech Co., Ltd.
Atopic Dermatitis
11/26
12/26
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery with or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC).

Completed
3
298
Europe, Canada, US, RoW
NovoTTF-200M device, Best Standard of Care
NovoCure GmbH
Brain Metastases from Non-small Cell Lung Cancer (NSCLC)
11/24
11/24
CYCLONE 2, NCT03706365 / 2016-004276-21: A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

Active, not recruiting
2/3
350
Europe, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone Acetate, Prednisone, Placebo
Eli Lilly and Company
Prostate Cancer
01/24
06/26
NCT06413654: A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)

Recruiting
2/3
132
RoW
B001, Placebo
Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd
Neuromyelitis Optica Spectrum Disorders
10/27
02/29
NCT04492293: An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer

Recruiting
2
115
RoW
ICP-192
Beijing InnoCare Pharma Tech Co., Ltd.
Bladder Urothelial Cancer
12/24
06/25
NCT06123858: Non-alcoholic Steatohepatitis Registry Platform Study

Recruiting
N/A
2500
RoW
AstraZeneca
NASH With Fibrosis
12/26
12/26
Peng, Xingchen
LIBRETTO-531, NCT04211337 / 2019-001978-28: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

Active, not recruiting
3
291
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib
Loxo Oncology, Inc., Eli Lilly and Company
Medullary Thyroid Cancer
05/23
02/26

Download Options